全文获取类型
收费全文 | 385篇 |
免费 | 23篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 13篇 |
妇产科学 | 8篇 |
基础医学 | 65篇 |
口腔科学 | 18篇 |
临床医学 | 30篇 |
内科学 | 48篇 |
皮肤病学 | 10篇 |
神经病学 | 50篇 |
特种医学 | 9篇 |
外科学 | 23篇 |
综合类 | 3篇 |
预防医学 | 29篇 |
眼科学 | 12篇 |
药学 | 49篇 |
中国医学 | 2篇 |
肿瘤学 | 39篇 |
出版年
2024年 | 2篇 |
2023年 | 8篇 |
2022年 | 7篇 |
2021年 | 29篇 |
2020年 | 9篇 |
2019年 | 11篇 |
2018年 | 15篇 |
2017年 | 12篇 |
2016年 | 13篇 |
2015年 | 19篇 |
2014年 | 22篇 |
2013年 | 26篇 |
2012年 | 42篇 |
2011年 | 37篇 |
2010年 | 20篇 |
2009年 | 20篇 |
2008年 | 23篇 |
2007年 | 20篇 |
2006年 | 10篇 |
2005年 | 9篇 |
2004年 | 11篇 |
2003年 | 12篇 |
2002年 | 11篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 2篇 |
1998年 | 2篇 |
1994年 | 2篇 |
1992年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1985年 | 1篇 |
1983年 | 1篇 |
1981年 | 2篇 |
1974年 | 1篇 |
排序方式: 共有410条查询结果,搜索用时 31 毫秒
1.
Dongbing Lai Emma C. Johnson Sarah Colbert Gayathri Pandey Grace Chan Lance Bauer Meredith W. Francis Victor Hesselbrock Chella Kamarajan John Kramer Weipeng Kuang Sally Kuo Samuel Kuperman Yunlong Liu Vivia McCutcheon Zhiping Pang Martin H. Plawecki Marc Schuckit Jay Tischfield Leah Wetherill Yong Zang Howard J. Edenberg Bernice Porjesz Arpana Agrawal Tatiana Foroud 《Alcoholism, clinical and experimental research》2022,46(3):374-383
2.
3.
Praerna H. Bhargav Preethi V. Reddy Ramajayam Govindaraj Kankan Gulati Arya Ravindran D. Gayathri Sneha J. Karmani Kaviraja Udupa Ganesan Venkatasubramanian Mariamma Philip Monojit Debnath Rose Dawn Bharath T. N. Sathyaprabha Bangalore N. Gangadhar Kesavan Muralidharan 《Revue canadienne de psychiatrie》2021,66(2):179
4.
5.
6.
Jennifer L. Allensworth Myron K. Evans Fran?ois Bertucci Amy J. Aldrich Richard A. Festa Pascal Finetti Naoto T. Ueno Rachid Safi Donald P. McDonnell Dennis J. Thiele Steven Van Laere Gayathri R. Devi 《Molecular oncology》2015,9(6):1155-1168
Cancer cells often have increased levels of reactive oxygen species (ROS); however, acquisition of redox adaptive mechanisms allows for evasion of ROS‐mediated death. Inflammatory breast cancer (IBC) is a distinct, advanced BC subtype characterized by high rates of residual disease and recurrence despite advances in multimodality treatment. Using a cellular model of IBC, we identified an oxidative stress response (OSR) signature in surviving IBC cells after administration of an acute dose of an ROS inducer. Metagene analysis of patient samples revealed significantly higher OSR scores in IBC tumor samples compared to normal or non‐IBC tissues, which may contribute to the poor response of IBC tumors to common treatment strategies, which often rely heavily on ROS induction. To combat this adaptation, we utilized a potent redox modulator, the FDA‐approved small molecule Disulfiram (DSF), alone and in combination with copper. DSF forms a complex with copper (DSF‐Cu) increasing intracellular copper concentration both in vitro and in vivo, bypassing the need for membrane transporters. DSF‐Cu antagonized NFκB signaling, aldehyde dehydrogenase activity and antioxidant levels, inducing oxidative stress‐mediated apoptosis in multiple IBC cellular models. In vivo, DSF‐Cu significantly inhibited tumor growth without significant toxicity, causing apoptosis only in tumor cells. These results indicate that IBC tumors are highly redox adapted, which may render them resistant to ROS‐inducing therapies. DSF, through redox modulation, may be a useful approach to enhance chemo‐ and/or radio‐sensitivity for advanced BC subtypes where therapeutic resistance is an impediment to durable responses to current standard of care. 相似文献
7.
8.
Aralikatte Onkarappa Saroja Karkal Ravishankar Naik Atcharayam Nalini Narayanappa Gayathri 《Annals of Indian Academy of Neurology》2013,16(4):712-715
Bethlem myopathy and Ullrich congenital muscular dystrophy form a spectrum of collagenopathies caused by genetic mutations encoding for any of the three subunits of collagen VI. Bethlem phenotype is relatively benign and is characterized by proximal dominant myopathy, keloids, contractures, distal hyperextensibility, and follicular hyperkeratosis. Three patients from a single family were diagnosed to have Bethlem myopathy based on European Neuromuscular Centre Bethlem Consortium criteria. Affected father and his both sons had slowly progressive proximal dominant weakness and recurrent falls from the first decade. Both children aged 18 and 20 years were ambulant at presentation. All had flexion contractures, keloids, and follicular hyperkeratosis without muscle hypertrophy. Creatinine kinase was mildly elevated and electromyography revealed myopathic features. Muscle imaging revealed severe involvement of glutei and vasti with “central shadow” in rectus femoris. Muscle biopsy in the father showed dystrophic changes with normal immmunostaining for collagen VI, sarcoglycans, and dysferlin.Key Words: Bethlem myopathy, collagen VI, contractures, immunohistochemistry, keloids 相似文献
9.
Eleanor S. Roberts Gursharan Chana Timothy B. Nguyen Gayathri Perera Sabine Landau Sophia Rabe-Hesketh Jonathan D. Glass Justin McArthur Ian Paul Everall 《Journal of neurovirology》2013,19(2):123-130
Specific neuronal spatial distributional patterns have previously been correlated with increasing severity of HIV-associated dementia (HAD). As astrocytes are also a putative site of neurotoxicity, we investigated the spatial relationships of astrocytes with pyramidal and interneurons in the superior frontal gyrus from 29 patients who died from acquired immunodeficiency syndrome. Frontal cortical brain tissue was taken from diseased HIV patients who had been assessed for the presence and severity of HAD using the Memorial Sloan-Kettering Scale. No correlation was found between neuronal density and severity of dementia. However, the pattern of astrocytes became more clustered as dementia progressed. Bivariate spatial pattern analysis of neuronal populations with astrocytes revealed that, with increasing dementia severity, astrocytes and large pyramidal neurons increasingly “repelled” each other, while astrocytes and interneurons evidenced increasing “attraction.” This implies that astrocytes may be more likely to be situated in the vicinity of surviving interneurons but less likely to be situated near surviving large pyramidal neurons in the setting of progressing HAD. 相似文献
10.
Jennifer L. Allensworth Scott J. Sauer H. Kim Lyerly Michael A. Morse Gayathri R. Devi 《Breast cancer research and treatment》2013,137(2):359-371
X-linked inhibitor of apoptosis protein (XIAP), the most potent mammalian caspase inhibitor, has been associated with acquired therapeutic resistance in inflammatory breast cancer (IBC), an aggressive subset of breast cancer with an extremely poor survival rate. The second mitochondria-derived activator of caspases (Smac) protein is a potent antagonist of IAP proteins and the basis for the development of Smac mimetic drugs. Here, we report for the first time that bivalent Smac mimetic Birinapant induces cell death as a single agent in TRAIL-insensitive SUM190 (ErbB2-overexpressing) cells and significantly increases potency of TRAIL-induced apoptosis in TRAIL-sensitive SUM149 (triple-negative, EGFR-activated) cells, two patient tumor-derived IBC models. Birinapant has high binding affinity (nM range) for cIAP1/2 and XIAP. Using isogenic SUM149- and SUM190-derived cells with differential XIAP expression (SUM149 wtXIAP, SUM190 shXIAP) and another bivalent Smac mimetic (GT13402) with high cIAP1/2 but low XIAP binding affinity (K d > 1 μM), we show that XIAP inhibition is necessary for increasing TRAIL potency. In contrast, single agent efficacy of Birinapant is due to pan-IAP antagonism. Birinapant caused rapid cIAP1 degradation, caspase activation, PARP cleavage, and NF-κB activation. A modest increase in TNF-α production was seen in SUM190 cells following Birinapant treatment, but no increase occurred in SUM149 cells. Exogenous TNF-α addition did not increase Birinapant efficacy. Neutralizing antibodies against TNF-α or TNFR1 knockdown did not reverse cell death. However, pan-caspase inhibitor Q-VD-OPh reversed Birinapant-mediated cell death. In addition, Birinapant in combination or as a single agent decreased colony formation and anchorage-independent growth potential of IBC cells. By demonstrating that Birinapant primes cancer cells for death in an IAP-dependent manner, these findings support the development of Smac mimetics for IBC treatment. 相似文献